Siemens said the has been " substantial progress in the preparation of the unprecedented transaction structure … [and] The separation process is advanced." ...

The firm intends to use the credit facility for liquidity support for its US dollar-denominated commercial paper program and for general corporate purposes.

The expanded panel includes 93 new microorganism-drug combinations, bringing the total panel size to 215, and in conformity with all the most current FDA breakpoints.

The Utrecht, Netherlands-based company recently closed a $70 million funding round and published trial results showing its technology's equivalence to manual blood collection.

Pathologists at academic medical centers are using intentional change-management strategies to overcome some intangible barriers digital uptake.

The firm's overall revenue rose 8 percent, driven by growth in established pharmaceuticals and medical devices.

The company's first Resolve blood-based multi-cancer detection tests are expected to be commercially available in the second half of 2026.

With the mark, the system, a fully automated blood culture platform meant for diagnosing bloodstream infections, can be sold throughout the EU.

The deal will help CHOP to expand the reach of its diagnostic innovations, allow Labcorp to grow its offerings, and enable the parties to combine resources to accelerate test development.

The test, which leverages technology that mimics a dog's ability to sense disease in humans, analyzes cancer-associated volatile organic compounds found in urine samples.

NEW YORK – Roche on Monday announced that it has received CE marking for a blood test to detect neuroinflammation in patients with multiple sclerosis. The Elecsys Neurofilament Light Chain test ...

MedStar Health will deploy PathAI's AISight for the more than 40 pathologists at its multi-site health system serving the Washington, D.C. area.